These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35719911)

  • 21. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.
    Zhou C; Li C; Yan F; Zheng Y
    Cancer Cell Int; 2020 Nov; 20(1):541. PubMed ID: 33292199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endoplasmic reticulum stress related IncRNA signature predicts the prognosis and immune response evaluation of uterine corpus endometrial carcinoma.
    Chen J; Shen L; Yang Y
    Front Oncol; 2022; 12():1064223. PubMed ID: 36686816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction of a prognostic model of luteolin for endometrial carcinoma.
    Zhao J; Jiao W; Sui X; Zou J; Wang J; Lin Z
    Am J Transl Res; 2023; 15(3):2122-2139. PubMed ID: 37056832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer.
    Lu N; Liu J; Ji C; Wang Y; Wu Z; Yuan S; Xing Y; Diao F
    Bioengineered; 2021 Dec; 12(1):3603-3620. PubMed ID: 34252354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying immune subtypes of uterine corpus endometrial carcinoma and a four-paired-lncRNA signature with immune-related lncRNAs.
    Li N; Yu K; Lin Z; Zeng D
    Exp Biol Med (Maywood); 2022 Feb; 247(3):221-236. PubMed ID: 34704492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
    Zhou M; Zhang Z; Zhao H; Bao S; Sun J
    BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of an integrated kinase-related prognostic gene signature associated with tumor immune microenvironment in human uterine corpus endometrial carcinoma.
    Wei S; Zhang J; Shi R; Yu Z; Chen X; Wang H
    Front Oncol; 2022; 12():944000. PubMed ID: 36158685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
    Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
    Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of the Prognostic Signature Associated With Tumor Immune Microenvironment of Uterine Corpus Endometrial Carcinoma Based on Ferroptosis-Related Genes.
    Liu J; Wang Y; Meng H; Yin Y; Zhu H; Ni T
    Front Cell Dev Biol; 2021; 9():735013. PubMed ID: 34692692
    [No Abstract]   [Full Text] [Related]  

  • 30. Identification of the prognostic value of a 2-gene signature of the WNT gene family in UCEC using bioinformatics and real-world data.
    Hu Y; Zheng M; Zhang D; Gou R; Liu O; Wang S; Lin B
    Cancer Cell Int; 2021 Sep; 21(1):516. PubMed ID: 34565373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma.
    Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR
    Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Endometrial Carcinoma to Immunotherapy and Chemotherapy.
    Liu J; Wang Y; Mei J; Nie S; Zhang Y
    Front Cell Dev Biol; 2021; 9():671736. PubMed ID: 34368124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive Analysis of Prognosis and Immune Landscapes Based on Lipid-Metabolism- and Ferroptosis-Associated Signature in Uterine Corpus Endometrial Carcinoma.
    Yang P; Lu J; Zhang P; Zhang S
    Diagnostics (Basel); 2023 Feb; 13(5):. PubMed ID: 36900015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Infiltrates of m5C RNA Methylation-Related LncRNAs in Uterine Corpus Endometrial Carcinoma.
    Gu WX; Chen Y; Wang W
    J Oncol; 2022; 2022():1531474. PubMed ID: 35392434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of immune-related gene signature for predicting prognosis in uterine corpus endometrial carcinoma.
    Song S; Gu H; Li J; Yang P; Qi X; Liu J; Zhou J; Li Y; Shu P
    Sci Rep; 2023 Jun; 13(1):9255. PubMed ID: 37286702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma.
    Zhao L; Fu X; Han X; Yu Y; Ye Y; Gao J
    Cancer Cell Int; 2021 Jan; 21(1):80. PubMed ID: 33509222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction of the novel immune risk scoring system related to CD8
    Zhang G; Yin Z; Fang J; Wu A; Chen G; Cao K
    Cancer Cell Int; 2023 Jun; 23(1):124. PubMed ID: 37349706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrative Analysis Reveals a Nine TP53 Pathway-Related lncRNA Prognostic Signature in Endometrial Cancer.
    Wang Y; Qu X; Li L; He D
    Biomed Res Int; 2022; 2022():5432806. PubMed ID: 36262972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening and validation of potential markers associated with uterine corpus endometrial carcinoma and polycystic ovary syndrome based on bioinformatics methods.
    Wu R; Wu C; Zhu B; Li J; Zhao W
    Front Mol Biosci; 2023; 10():1192313. PubMed ID: 37363398
    [No Abstract]   [Full Text] [Related]  

  • 40.
    Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
    Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.